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When a major study finds that a widely used medical treatment is no better than a less expensive alternative,
do physicians stop using it? Policymakers hope that comparative effectiveness research will identify
less expensive substitutes for widely-used treatments, but physicians may be reluctant to abandon
profitable therapies. We examine the impact of the COURAGE trial, which found that medical therapy
is as effective as percutaneous coronary intervention (PCI) for patients with stable angina, on practice
patterns. Using hospital discharge data from US community, Veterans Administration, and English
hospitals, we detect a moderate decline in PCI volume post-COURAGE. However, many patients
with stable angina continue to receive PCI. We do not find differences in PCI volume trends by reimbursement
scheme or hospitals’ teaching status, ownership, or degree of vertical integration.
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When a major study finds that a widely used medical treatment is no better 
than a less expensive alternative, do physicians stop using it? The Patient 
Protection and Affordable Care Act (i.e., the health reform bill) includes a dedicated 
funding stream for comparative effectiveness research, which subjects competing 
treatments to head-to-head trials, of approximately $500 million annually. The 
premise behind comparative effectiveness research is that expensive treatments 
often diffuse into clinical practice without evidence that they are better than 
existing therapies (Chandra et al. 2011). Policymakers hope that comparative 
effectiveness studies will identify ineffective but costly treatments, leading to cost 
savings. However, it is unclear how evidence from comparative effectiveness 
research studies, and studies that report “negative” results in particular, influence 
medical treatment patterns. The same factors that promote rapid adoption of new 
medical technologies – fee for service reimbusement, third party payment, etc. 
(Emanuel and Fuchs 2008) – may retard the abandonment of widely-used 
technologies found to be ineffective.  
Percutaneous coronary intervention (PCI) is an invasive procedure to open 
clogged coronary arteries. Medicare spent over $5 billion on PCIs in 2005 
(Committee on Finance 2010). In 1999 the Department of Veterans Affairs initiated 
a multi-million dollar study, the COURAGE trial, to compare PCI and medical 
therapy versus an inexpensive regimen of medical therapy alone in patients with 
stable angina. The study, which was published in April 2007 in the New England 
Journal of Medicine (Boden et al. 2007), found that the treatments were equivalent 
in terms of survival time and heart attack risk. In this paper, we assess the impact 
of the widely-publicized COURAGE trial on the abandonment of PCI as a treatment 
for stable angina. We also compare trends in PCI volume between 1) health systems 
where cardiologists are compensated via fee-for-service and systems where 
cardiologists are salaried and 2) hospital organizational environments that may 
affect physicians’ responsiveness to negative evidence. While it is difficult to 4 
 
precisely identify the impact of the COURAGE trial in light of pre-existing trends, 
our results suggest that 1) COURAGE had a small-to-moderate impact on practice 
patterns and 2) many patients with stable coronary disease continue to receive PCI 
as primary therapy.  
 
2. Technological abandonment  
 
2.1 Adoption and abandonment 
 
New medical technology is responsible for most of the growth in health care 
spending (Newhouse 1992). Naturally, there is an extensive literature on technology 
diffusion in health care. Few papers address technological abandonment, either in 
health care or non-health care settings.1 Abandonment may be uncommon outside 
of health care settings because unsuccessful innovations are quickly jettisoned and 
only successful innovations are widely adopted. In health care, by contrast, many 
technologies diffuse into clinical practice without evidence of benefit (Fuchs 1968; 
1986). Given that randomized controlled trials are costly and the knowledge they 
produce is a public good, production of evidence will be suboptimal (Murphy and 
Topel 2006), a market failure that federally- sponsored comparative effectiveness 
research is designed to address.  
A number of factors may push physicians to adopt untested therapies, 
including reimbursement incentives, manufacturer’s marketing efforts, a desire to 
achieve prestige through technology acquisition, and a cultural faith in 
technological progress (Emanuel and Fuchs 2008; Teplensky et al. 1995).2 
Once adopted, unproven technologies often remain in use. Most models of 
adoption under uncertainty assume that producers eventually learn whether the 
                                                            
1 Technological abandonment refers to instances where a technology is replaced by 
an older, pre-existing treatment alternative or technology. 
2 David Eddy (1984), an early advocate of  comparative effectiveness research, has 
described the prevaling mindset as “When in doubt, do it”. 5 
 
new technology is better than the old one (Young 2009), but physicians may never 
learn about the effectiveness of new treatments absent large randomized controlled 
trials. Patient outcomes are variable, making it difficult to draw inferences about 
effectiveness based on the patient panel of a single physician or hospital. In 
situations where patients receive treatment in one setting but follow-up care in 
another, physicians may not even observe outcomes in their own patient 
populations.  
 
2.2 Reimbursement incentives 
 
Comparative effectiveness studies that pool patients from multiple providers 
can overcome the inherent limitations of inferring treatment effects based on the 
historical experience of a single physician or hospital. Physicians’ incentives to act 
on new information vary based on how they are compensated. Barros and Martínez-
Giralt (2010) model adoption of a new technology under different reimbursement 
arrangements assuming that providers value their own financial performance and 
patient health. They show that when providers earn higher margins on the new 
technology, they may adopt the treatment even if it provides no benefit to patients.  
Under Medicare’s resource based relative value scale, which is widely used by 
private payers in the US, payments for PCI are higher than payments for medical 
management. Medicare’s 2011 payment to a physician for insertion of a stent is 
$873 (Current Procedural Terminology code 92980). The payment for an office visit 
for medical management is about $54 (code 90862). Comparing these payments does 
not precisely represent the incentives facing physicians – physicians may bill for 
multiple services during a PCI and patients on medication may require multiple 6 
 
visits – but it does give a sense of the magnitude of the difference in reimbursement 
levels.3,4  
The market for PCI is particularly prone to physician-induced demand. 
Cardiologists often act as both diagnosticians and proceduralists. Patients with 
stable angina are referred for diagnostic imaging to define both the extent and 
severity of obstructive coronary artery disease. The imaging process requires that 
patients undergo cardiac catheterization. Once the patient has been prepped, 
anesthetized, and the cardiologist has established arterial access, it is relatively 
straightforward to perform PCI. Some observers argue that this process leads to a 
“diagnostic-therapeutic cascade” where patients initially brought in for evaluation 
end up undergoing PCI.5 Because PCI often immediately follows diagnosis, patients 
and insurers have relatively little input into the care process.  
Most empirical analyses find evidence consistent with the prediction that low 
powered reimbursement schemes (e.g. fee-for-service) are associated with greater 
use of technology. A study of the diffusion of PCI and bypass surgery for heart 
attack patients in industrialized countries found that diffusion tended to be more 
rapid in countries where reimbursement systems favor adoption (Bech et al. 2009; 
TECH Research Network 2001).6 Baker and Phibbs (2002), Baker and Wheeler 
                                                            
3 Medicare and other insurers make payments to physician groups, not individual 
physicians. However, most cardiology groups closely link physician compensation 
with procedure volume. 
4 PCI is performed in hospitals while medical therapy is administered in physicians’ 
offices, and so, hospitals benefit when physicians recommend PCI. Medicare 
hospital payments for PCI range from $10,000 to $18,000. Federal law prohibits 
hospitals from providing monetary incentives to non-employed physicians for 
referring patients, but they can offer marketing and support services that serve as 
subtler inducements to recommend hospital-based care.  
5 Cardiologists jokingly refer to the “oculostenotic reflex” that causes them to 
automatically perform PCI once the see evidence of a blockage (i.e. stenosis). 
6 Baker and Wheeler (1998) find that the number of MRI machines per capita was 
negatively associated with the market share of health maintenance organizations in 
the mid 1990s. It is unclear if the correlation is driven by reimbursement policies, 7 
 
(1998), and Mas and Seinfeld (2008) report that managed care slowed the adoption 
of cost-increasing medical technologies, though Baker and Spetz (1999) find no 
evidence of a managed care effect. Studies of the impact of the Medicare prospective 
payment system on technology adoption and use report mixed effects (Acemoglu and 
Finkelstein 2008; Kane and Manoukian 1989; Sloan et al. 1988), possibly reflecting 
the complex set of incentives inherent in the payment scheme (McClellan 1997). 
 
2.3 Organizational form 
 
Another factor that may retard abandonment of ineffective technologies is 
organizational fragmentation in the health system. Physician practice is organized 
around single specialty groups. Many observers have remarked that under this 
arrangement, physicians do not focus on the “whole patient”. Rather, organizations 
in health care are organized around delivering specific medical technologies 
(Enthoven and Tollen 2005; Schroeder and Showstack 1977). For example, 
cardiologists deliver PCI. Specialists may be reluctant to abandon the technologies 
that help to define their specialty.  
Integrated health systems that are able to provide multiple treatments may 
display more flexibility in responding to comparative effectiveness research, 
especially in cases where patients in non-integrated systems must cross 
organizational boundaries to access alternative treatments.  
Counteracting this effect, integrated delivery systems that are subject to fee-
for-service reimbursement may encourage its physicians to engage in “self referral”. 
In the case of stable angina, an integrated system could increase its revenues by 
promoting referrals from primary care physicians and non-interventional 
cardiologists to interventional cardiologists. Studies of the entry of physician-owned 
cardiac specialty hospitals (Barro et al. 2006; Mitchell 2007; Nallamothu et al. 2007; 
                                                                                                                                                                                                 
other forms of cost control (e.g., utilization review), or unobserved market 
characteristics. 8 
 
MedPAC 2006) and 1990s-era physician-hospital alignment (Madison 2004; Cuellar 
and Gertler 2006) find that integration is associated with increased volume and 
treatment intensity. For this reason, the Patient Protection and Affordable Care Act 
severely limits entry of new physician-owned specialty hospitals. 
Other characteristics of providers may influence their receptivity to negative 
results. Private hospitals (especially for-profits), for example, have a strong 
incentive to invest in innovation that might be difficult to relinquish because of 
sunk costs (Grossman and Hart 1986; Hart 1995; Hart, Shleifer and Vishny 1997). 
Physicians practicing in for-profit hospitals may be less willing to abandon lucrative 
treatments. Hospitals whose mission involves educating the next generation of 
physicians, i.e. teaching hospitals, or those that specialize in cardiac care might be 
more receptive to studies that demonstrate “best practice” treatment options. 
 
2.4 Empirical evidence 
 
Few studies have examined the impact of comparative effectiveness research 
studies reporting negative results.7 Duffy and Farley (1992) describe the impact of 
negative trial results on use of intermittent positive pressure breathing therapy as 
a treatment for chronic obstructive pulmonary disease. They found that use was 
slow to decline, and many patients continued to receive the therapy four years after 
the results were published. Stafford et al. (2006) studied abandonment of costly 
calcium channel blockers and angiotensin-converting enzyme inhibitors for patients 
with hypertension following negative trial results. They found that evidence had a 
“modest” effect on use but many patients continued to receive these drugs as first-
line therapy. A high profile 2002 study failed to find evidence of a benefit of 
arthroscopy for osteoarthritis of the knee (Moseley et al. 2002). There was a slight 
                                                            
7 The impact of disclosure of previously unknown side effects on abandonment has 
been widely studied. Here, we restrict attention to the impact of trials that report 
equivalence results. 9 
 
decline in use in England and Ontario between 2002 and 2004 in patients with a 
diagnosis of osteoarthritis, though there were increases in the use of the procedure 
for other diagnoses (Hawker et al. 2008). Howard et al. (forthcoming) report that 
use of high dose chemotherapy followed by autologous hematopoietic stem cell 
transplantation declined rapidly following the release of negative clinical trial 
results.  
 
3. The COURAGE trial 
 
Chronic stable angina is characterized by chest pain during exertion caused 
by a narrowing of the coronary arteries. Treatment options include 
revascularization via PCI or a low cost regimen of medical therapy and lifestyle 
modification. PCI entails cardiac catheterization, use of balloon angioplasty to 
mechanically open the artery, and, in most cases, placement of a stent to maintain 
blood flow. The Department of Veterans Affairs-sponsored Clinical Outcomes Using 
Revascularization and Aggressive Drug Evaluation (COURAGE) trial randomized 
2,287 patients with stable angina to receive optimal medical therapy alone or PCI 
plus medical therapy between 1999 and 2004.  
The main finding from COURAGE was that there was no difference between 
treatment arms in all-cause mortality or acute myocardial infarction (AMI). The 
results, which were published in the New England Journal of Medicine in April 
2007, were widely publicized and “shook the world of cardiology” (Winstein 2010).8  
A subsequent analysis found that while patients in the PCI arm experienced 
earlier resolution of symptoms, quality of life was no different after 3 years 
(Weintraub 2008). Based on COURAGE results, Weintraub et al. (2008) calculate 
                                                            
8 Some cardiologists have questioned the external generalizability of the COURAGE 
trial and its relevance to current cardiology practice (Curzen 2010).We do not wish 
to weigh in on this debate, except to note that specialists may be more likely to 
scrutinze studies that will potentially result in revenue-reducing practice changes. 10 
 
that lifetime costs for stable ischemic heart disease patients treated with PCI are 
over $9,000 higher than for patients treated with optimal medical therapy alone. 
Prominent cardiologists perceive that fee-for-service reimbursement is a 
major obstacle to implementing the COURAGE results. Peterson and Rumsfeld 
(2008) write: “[The COURAGE trial] underscores a major challenge to clinicians — 
how to successfully execute a strategy of optimal medical therapy in a health care 
system that provides strong financial incentives for PCI but few rewards for careful 
management of medications.” The principal investigator of the COURAGE trial, Dr. 
William Boden, echoed these sentiments: “What’s going to continue to drive practice 
is reimbursement,” (Winstein 2010).  
A handful of studies have examined the impact of the COURAGE trial and 
the appropriateness of care for patients with stable angina. An analysis of data from 
10 hospitals in Maine, New Hampshire, and Vermont found that there was a 16% 
decline in PCI volume post-COURAGE (Ahmed et al. 2011). The proportion of 
patients receiving PCI who had a diagnosis of stable angina (i.e. the target 
population of the COURAGE trial) declined from 21% to 16%. Borden et al. (2011) 
analyzed changes in the use of optimal medical therapy in patients undergoing PCI 
before and after publication of the COURAGE trial. He found that there was a 1 
percentage point increase in receipt of medical therapy post-COURAGE. The study 
restricted attention to patients receiving PCI and did not report trends in PCI 
volume. Chan et al. (2011) used a rating system to assess the appropriateness of 
PCIs performed at 1,091 US hospitals between July 1, 2009, and September 30, 
2010. Of the 500,154 procedures they examined, 144,737 (29%) were for stable 
angina. Of these, 72,911 (50%) were rated as “appropriate”, 54,988 (38%) were rated 
as “uncertain”, and 16,838 (12%) were rated as inappropriate. Only the Ahmed et al. 
paper tracks trends in PCI volume over time, but the sample of hospitals is small 
and self-selected. Whether COURAGE affected practice patterns in the US and 
other health systems remains an open question. 
 11 
 




Using data capturing discharges from US community hospitals, US Veterans 
Administration hospitals, and English National Health Service hospitals, we 
analyze trends in PCI volume by indication. In each case, we report the number of 
discharges per quarter. The data include records for inpatient PCIs and so-called 
“23-hour admissions” for PCI. We identified patients undergoing PCI using 
procedure codes. 9  We do not have data on receipt of medical therapy. Medical 
therapy is administered on an outpatient basis. It is difficult to identify patients 
with stable angina who are receiving medical therapy as an alternative to PCI in 
standard claims databases. 
 
4.2 US Community Hospitals 
 
Figure 1 presents long-run trends in quarterly PCI volume from the National 
Hospital Discharge Survey (NHDS), a random sample of hospital discharges in US 
community hospitals. The sample size is over 300,000 in most years but, because of 
budget cuts, is only 120,000 in 2008. NHDS includes sample weights for producing 
national estimates of procedure volume. 
We group patients into two mutually exclusive categories. The “Other 
diagnoses, Elective” group includes patients without a diagnosis of AMI where the 
admission type was recorded as “Elective”. The “AMI and Other diagnoses, Non-
Elective” group includes all patients with a diagnosis of AMI and patients with 
other diagnoses with an “urgent” or “emergency” admission. The first group 
                                                            
9 The codes for PCI are 36.01, 36.02, 36.05, 36.06, 36.07, and 36.09. These are often 
preceded by code 00.66.  12 
 
includes many patients who would have met the COURAGE inclusion criteria, 
though there may be some patients who would have been excluded.  
The data show that PCI volume in the “Other diagnoses, Elective” group 
plateaued between 2003 and 2006 but declined rapidly following publication of the 
COURAGE trial. There was also a decrease in PCI volume in late 2007 among 
patients in the “AMI and Other diagnosis, Non-elective” group (note that the y-axis 
for this group is compressed). A paper presented at a September 2006 cardiology 
meeting raised concerns about the safety of drug-eluting stents, a device used in a 
large share of PCIs.10 Although cardiologists could have substituted bare metal 
stents, the findings, which have been contradicted by subsequent research, 
temporarily depressed demand for PCI among patients regardless of diagnosis.  
Figure 2 presents PCI volume trends in Arizona, California, Florida, 
Massachusetts, Maryland, New Jersey, and New York using the State Inpatient 
Discharge databases. These databases capture 100% or close to 100% of hospital 
discharges, depending on the state.11  
Arizona, California, Florida, Massachusetts, Maryland, New Jersey, and New 
York represent about 35 percent of US population. The average PCI rate per 1,000 
fee-for-service Medicare enrollees in these states in 2007, as reported by The 
Dartmouth Atlas of Health Care (2011), is 9.8, with a range of 7 (Massachusetts) to 
11.9 (Arizona). Nationally, the rate is 10 with a range of 3 (Hawaii) to 14.3 
(Arkansas).   
We grouped patients into two categories 1) Stable Angina/Other and 2) 
AMI/Unstable angina.12 Patients in the first group include those with a diagnosis of 
                                                            
10 Camenzind E, Steg PG, Wijns W. A metaanalysis of first generation drug eluting 
stent 
programs. Presented at Hotline Session I, World Congress of Cardiology 2006, 
Barcelona, September 2–5, 2006. abstract. 
11 The advantage of using these data, as opposed to databases that randomly 
sample hospitals, is that trends in procedure volume are not affected by year-to-
year changes in the sample of hospitals. 
12 The ICD-9 codes are AMI: 410.X, and unstable angina: 411.1. 13 
 
stable angina or with a general ischemic heart disease diagnosis code but no 
diagnosis of AMI or unstable angina. Stable angina is rarely recorded as a 
diagnosis, and so it is not possible to specifically identify these patients. The second 
category includes patients with a diagnosis of heart attack (i.e. acute myocardial 
infarction [AMI]) or unstable angina. These patients have serious, acute symptoms 
that require immediate medical attention.  
Pre-COURAGE, patients with stable angina accounted for one-third of PCI 
procedures (Peterson and Rumsfeld 2008), so it likely that a large share of patients 
in the Stable Angina/Other group would have satisfied the COURAGE inclusion 
criteria. None of the patients in the AMI/Unstable angina would have been 
considered candidates for COURAGE.  
Figure 2 shows that PCI volume in the Stable Angina/Other group declined 
following publication of the COURAGE trial. For reasons that are unclear, PCI 
volume declined between the second and third quarters of 2006. However, based on 
the results presented in Figure 1, it does not appear that this was a continuation of 
a pre-existing trend.  
PCI volume also declined among patients with a diagnosis of AMI or unstable 
angina between the first and second quarters of 2007. The decline may reflect 
concerns about the safety of drug-eluting stents or an informational spillover of the 
COURAGE trial to excluded patient groups.  
Our reading of the data in Figures 1 and 2 is that publication of the 
COURAGE trial led to a decrease in PCI volume. However, many patients with 
stable coronary syndrome continue to receive PCI. 
 
4.3 Veterans Administration hospitals 
 
Figure 3 displays PCI volume trends in Veterans Administration medical 
centers. We calculated trends using the Patient Treatment File, a census of 
discharges from US Veterans Administration Medical Centers. Like the State 14 
 
Inpatient Discharge databases, the Patient Treatment File includes diagnoses codes 
but does not allow us to specifically identify patients meeting the COURAGE trial 
inclusion criteria.  
Veterans Administration hospitals are notable in several respects. First, 
many Veterans Administration hospitals enrolled patients in the COURAGE trial. 
Second, cardiologists in the Veterans Administration are salaried and hospitals are 
subject to a global budget. Some cardiologists split their time between Veterans 
Administration hospitals and academic medical centers. Their practice styles may 
fall in-between the practice patterns of physicians subject to salary or fee-for-service 
reimbursement alone.  
The data show that PCI volume declined post-COURAGE in the Stable 
angina/Other group but was steady in the AMI/Unstable angina group. 
 
4.4 English hospitals 
 
Figure 4 displays trends in PCI volume in English hospitals. We calculated 
PCI volume using the Hospital Episode Statistics database, a census of discharges 
from English National Health Service hospitals. The data include diagnosis codes, 
but not other clinical indicators, and capture admissions by private pay patients. 
English cardiologists are salaried. Prior to 2002, hospitals were subject to 
budgets. In 2002 the National Health Service adopted a fee-for-service-like 
reimbursement scheme, “Payment by Results” that pays hospitals for each 
admission, similar to Medicare’s prospective payment system. Based on the trends 
depicted in the Figure, it does not appear that the COURAGE trial had an impact 






4.5 US-VA-England comparison 
 
Aggregate trends in PCI volume are summarized in Table 1. The table also 
displays PCIs per 100,000 persons age 45 and older in the US and UK populations 
and the number of patients admitted with a diagnosis of AMI, a rough measure of 
trends and cross-sectional differences in the underlying prevalence of heart disease. 
According to the SID and NHDS, PCI volumes declined between 2006 and 
2008 in US community hospitals. The magnitude of the decline in percentage terms 
was much larger in the Stable angina/Other and Elective groups.  
PCI rates in the US are much higher than those in England, possibly 
reflecting differences in disease prevalence. Banks et al. (2006) report that the 
prevalence of heart disease is anywhere from 20% to 50% higher in the US versus 
the UK. However, we find that the AMI rate (column 3 of the table) is similar. 
Differences in PCI rates may also reflect differences in practice patterns. Heart 
attack patients in Canada and the UK are substantially more likely to receive PCI 
or surgery compared to patients in the US (Adams et al. 1998; Kaul et al. 2005; 
Mark et al. 1994; Rouleau et al. 1993; TECH Research Network 200; Yusef et al. 
1998.) 
PCI rates did not decline in England following COURAGE. Pre-COURAGE 
PCI rates were lower in England, and so there may have been fewer opportunities 
to substitute medical therapy for PCI. Yet, over half the patients undergoing PCI in 
the UK receive the procedure for stable angina and other forms of stable coronary 
disease (NHS Information Center 2007), and so there are probably many patients 
receiving PCI who could be safely treated using medical therapy. 
The impact of COURAGE on PCI volume in England may have been 
dampened by capacity constraints. Historically the demand for PCI has exceeded 
PCI capacity, resulting in waiting lists. Capacity constraints have a smoothing 
effect on realized procedure volume. Not surprisingly, we find that there is little 16 
 
quarter-to-quarter variation in PCI volume in England (Figure 4) compared to the 
US (Figure 3).  
If demand exceeds capacity, then a shift from PCI to medical therapy would 
show up as a decline in waiting times rather than a change in observed procedure 
volume. In our sample, waiting time among patients in the Stable angina/Other 
group declined from 53 days in 2006 to 37 days in 2008. Waiting time among 
patients with AMI/Unstable angina declined from 49 days to 32 days.  
 
5. Organizational environment 
 
Hospitals’ organizational environment may affect how physicians responded 
to the COURAGE trial. We assess the impact of hospitals’ organizational 
environment within the US by linking the State Inpatient Discharge data with 
hospital characteristics from the American Hospital Association (AHA) annual 
survey from 2006 to 2009. The estimation sample consists of hospital-quarter of 
year observations.  
We estimated regression models of the following form: 
 











it w x CRG PCI PCI                







/  are the number of PCIs performed in hospital i at time 
t in patients with stable angina/other diagnoses and AMI/unstable angina, 
respectively.  t CRG  is an indicator equal to one following publication of the 
COURAGE trial, 
j
i x  are a set of time-invariant hospital characteristics, 
k
it w  are a set 
of time-variant hospital characteristics,  i  are hospital-specific fixed effects,  t   are 
year and quarter fixed effects, and  it   is an i.i.d. error term.  
Hospital-level PCI volume is highly skewed, and so we chose to specify the 
dependent model as a difference, rather than controlling for 
UA AMI
it PCI
/  on the right 17 
 
hand side of the regression, to “normalize” the residuals. Hereafter, we refer to the 
dependent variable as “relative PCI volume.”  Standard errors were adjusted for 
clustering using the approach described by Stock and Watson (2008).  
We estimated specifications where observations were weighted by hospital’s 
average PCI volume, but results were similar to those from the unweighted 
specification, and so we report the unweighted results.  
In this model, the year and quarter indicators capture the macro and 
seasonal trends of the PCI volume between 2004 and 2009. The hospital fixed 
effects control for any unobserved time-invariant heterogeneity across hospitals. 
Table 2 displays summary statistics of the sample, and annual PCI volume by 
indication for each type of hospital (pooled across all years). 
The variables of interest are the interaction terms between the COURAGE 
indicator and the hospital time-invariant characteristics. As discussed previously, 
we expect that physicians in for-profit hospitals may be less likely to abandon 
profitable treatments and physicians in teaching hospitals ought to be more 
responsive to new evidence. We include indicators for ownership (for-profit, not-for-
profit, government) and for whether the hospital is a teaching hospital, as indicated 
by membership in the Council of Teaching Hospitals.13  Physicians practicing in 
integrated delivery systems may be better able to switch between alternative 
treatments, but may face added pressure to refer patients for profitable treatments. 
We include the following indicators to capture this dimension: 1) whether a hospital 
is in a joint venture with physicians or physician groups and 2) whether a hospital 
is part of a health delivery system with highly centralized physician arrangements. 
We also examine whether hospitals that offer cardiac surgery were more or less 
responsive to the results of the COURAGE trial. We use this measure, along with 
the number of AMI admissions, as proxy for the size of the cardiac care program in 
                                                            
13 We also estimate the model with different definition of teaching hospitals, such as 
if the hospital has a resident program, if the hospital is affiliated with a medical 
school, and our results are similar using various teaching hospital definition. 18 
 
a given hospital.  
Table 3 displays results. Models 1 through 4 include different hospital 
characteristics. Model 5 includes all characteristics. All models include a constant 
term, a post-COURAGE indicator, which takes the value of 1 from the 2nd quarter of 
2007 onward, and year-specific indicators. The post-COURAGE indicator and the 
year-specific indicators combined capture the average impact of the COURAGE 
trial. The interactions of the post-COURAGE indicator and hospital characteristics, 
which are of primary interest, capture the differential effect of the COURAGE trial 
on different types of hospitals. 
We do not find that COURAGE had a differential impact on relative PCI 
volume by hospital ownership, teaching status, whether there is a joint venture 
with physician groups, and whether the hospital is part of a centralized health 
system. On the whole, these results are consistent with previous studies of 
abandonment that have failed to identify differential effects of hospital ownership 
or teaching status on abandonment rates (Howard et al., forthcoming, Duffy and 
Farley 1992), though Duffy and Farley found that hospitals that were part of multi-
hospital systems were quicker to relinquish intermittent positive pressure 
breathing therapy. 
Model 4 indicates that there was a larger decline in relative PCI volume in 
hospitals that offer cardiac surgery. In addition, there were steeper declines in 
relative PCI volume over the study period in hospitals with greater numbers of AMI 
admissions. These trends may reflect increases in the number of hospitals offering 
PCI and the greater acceptability of performing PCI without having bypass surgery 
as a backup. We would expect that new entrants and hospitals that offer PCI 
without performing bypass surgery would draw away patients with less serious 
forms of cardiac disease from the larger, more established programs. We assessed 
this hypothesis by estimating a version of the model with a control variable for the 
number of hospitals offering PCI within a given hospital’s market area (defined as 
within a 15-mile radius) in each year.  The inclusion of this variable did not change 19 
 
the original results. It is also possible that larger cardiac program might have more 
resources and a wider variety of care management options to substitute non-
invasive for invasive care. 
We estimated a number of alternative specifications, weighting the 
regression by average PCI volume, limiting the sample to hospitals that performed 
more than 25 PCIs in 2006, and using the percent of PCIs performed in patients 
with stable angina/other indications as the dependent variable. In all cases, results 




If medical practice patterns respond asymetrically to postive and negative 
evidence – physicians adopt new treatments based on “positive” results but do not 
abandon existing ones following “negative” studies – then comparative effectiveness 
research is unlikely to reduce spending and may very well lead to increased costs. 
We find, encouragingly, that COURAGE had an impact on the use of PCI within the 
US. However, many patients with stable angina continue to receive PCI as primary 
therapy, a result confirmed in a recent audit of PCIs performed in 2009 (Chan et al. 
2011). There are unexploited opportunities to reduce costs without adversely 
affecting outcomes by substituting medical therapy for PCI.  
Prominent cardiologists were pessimistic about the potential impact of 
COURAGE in the US given the incentives facing cardiologists. However, we find 
that the post-COURAGE decline in PCI volume was larger in US community 
hospitals compared to Veterans Administration and English hospitals, where 
cardiologists are salaried. It is difficult to interpret differential trends in PCI 
volume in light of baseline differences in practice patterns, but the results suggest 
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Source: Authors' analysis of the Veterans Administration Patient Treatment File.
PCI: percutaneous coronary intervention
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Source: Authors' analysis of Hospital Episode Statistics database.
PCI: percutaneous coronary intervention
Figure 4: Quarterly PCI volume by indication, EnglandTable 1: Change in PCIs and AMIs, 2006 to 2008
2006 74 [274] 79 [292] 176 [653]
2008 57 [210] 72 [266] 172 [639]
Change -17 (-30%) -7 (-10%) -4 (-2%)
2006 15.8 4.5
2008 14.1 4.8
Change -1.7 (-12%) 0.2 (5%)
2006 36 [169] 20 [94] 140 [650]
2008 36 [169] 24 [114] 140 [652]
Change 0 (0%) 4 (18%) 0.5 (0%)
2006 137 [116] 500 [420] 812 [682]
2008 84 [70] 439 [369] 825 [693]
Change -54 (-64%) -61 (-14%) 13 (2%)
aTotal admissions for acute myocardial infarction.
bThe total population for the VA is undefined. We do 
  not have data on total AMI admissions.
PCI: Percutaneous coronary intervention. 
AMI: Acute myocardial infarction (i.e. heart attack).
SID: State Inpatient Discharge data.
NHDS: National Hospital Discharge Survey.
SID: State Inpatient Discharge data from AZ, CA, FL,
MA, MD, NJ, NY.
PCIs
Stable angina/ AMI/Unstable AMI
Other angina  Admits
b 
United States: NHDS
No. (1,000s) [Rate per 100K persons age≥45]
United States: SID 
United States: Veterans Administration
b
England: Hospital Episode Statistics
Elective Non-electiveStable angina/
Not-for-profit 380 (70) 45 (74) 56 (73) -11 (43)
For-profit 103 (19) 32 (41) 44 (49) -12 (26)
Government 60 (11) 31 (41) 47 (53) -16 (30)
Teaching 103 (19) 77 (103) 81 (86) -4 (59)
Joint venture 168 (31) 50 (74) 65 (81) -15 (44)
Centralized system 60 (11) 62 (85) 78 (83) -15 (47)
Cardiac surgery 288 (53) 67 (78) 80 (75) -13 (50)
All hospitals 543 (100) 41 (66) 53 (67) -12 (39)
AMI admissions/year 99 (76)
Bed size 385 (344)
Number of hospitals 543
N (%/SD) N (SD)
Table 2:  Characteristics of the hospitals included in the sample
Relative 







  0.3 (1.52)
 
×For profit 2.0 (2.11)
  0.6 (2.21)
 
×Government 3.0 (2.75)
  3.4 (2.89)
 
×Teaching -3.5 (3.13)
  -1.3 (3.32)
 
×Joint venture 0.8 (1.71)
  2.6 (1.85)
 
×Centralized system -2.9 (3.83)
  -2.1 (3.81)
 
×Cardiac surgery -7.1 (1.90)
* -7.3 (2.01)
*






Bed size 0.6 (0.41)
  0.8 (0.44)
  0.6 (0.40)





















2nd quarter 1.0 (0.62)
  1.0 (0.61)
  1.0 (0.61)
  0.9 (0.61)
  0.9 (0.61)
 


















The unit of observations is the hospital-quarter. There are 8,176 observations. 
All models include hospital fixed effects.
*p<0.05
AMI: Acute myocardial infarction
Table 3: The impact of hospital characteristics on the difference in the number of PCIs in patients 
with stable angina/other indications versus unstable angina/AMI
B (SE)
Model
(1) (2) (3) (4) (5)